RECRUITING

Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) \< 30% or isolated right congenital diaphragmatic hernia (RCDH) with O/E LHR \< 45%,to compare survival to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation and isolated LCDH with O/E LHR \< 30% that receive FETO procedure performed at 27 weeks 0 days to 29weeks 6 days of gestation to those with intrathoracic liver herniation, isolated LCDH and o/e LRH \< 30% that undergo expectant management, to compare the neonatal survival rate to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation, isolated RCHD with o/e LHR \< 45% that undergo FETO procedure performed at 27 weeks 0 days to 29 weeks 6 days gestation to those with intrathoracic liver herniation, isolated RCHD and o/e LHR \< 45% that elect to proceed with expectant management, to evaluate the frequency of maternal and fetal complications associated with FETO procedure, to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated LCDH survivors with o/e LHR \<30% when compared to isolated LCDH with o/e LRH \<30% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation and to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated RCDH survivors with o/e LHR ≤ 45% when compared to isolated RCHD with LHR \< 45% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation.

Official Title

North American Fetal Therapy Network Prospective Registry for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia

Quick Facts

Study Start:2025-06-23
Study Completion:2031-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07166172

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Pregnant women who are able to consent
  2. * Singleton pregnancy
  3. * Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, whole exome sequencing (WES) or whole genome sequencing (WGS) . Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \> 26 weeks
  4. * Gestational age at enrollment is prior to 296 wks.
  5. * Intrathoracic liver herniation
  6. * Isolated left CDH with o/e LHR \< 30% at enrollment (180 to 295 wks.) or
  7. * Isolated RCDH with o/e LHR \< 45% at enrollment (180 to 295 wks.)
  8. * Cervical length by transvaginal ultrasound \> 20 mm within 24 hours prior to FETO procedure
  9. * Patient meets psychosocial criteria
  10. * Informed consent understood
  1. * History of natural rubber latex allergy
  2. * Preterm labor, cervix shortened (\<20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.
  3. * Psychosocial ineligibility, precluding consent:
  4. 1. Inability to reside within 30 minutes of Johns Hopkins Hospital Center for Fetal Therapy.
  5. 2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Johns Hopkins Hospital Center for Fetal Therapy.
  6. * Bilateral CDH, isolated left sided CDH with O/E LHR ≥ 30% (measured at 180 to 295 weeks), isolated right sided CDH with O/E LHR \> 45% (measured at 180 to 295 weeks), as determined by ultrasound
  7. * No liver herniation into thoracic cavity
  8. * Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).
  9. * Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy
  10. * History of incompetent cervix with or without cerclage
  11. * Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  12. * Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  13. * Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
  14. * Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality
  15. * There is no safe or technically feasible fetoscopic approach to balloon placement
  16. * Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy

Contacts and Locations

Study Contact

Ahmet Baschat, MD
CONTACT
410-502-6561
abascha1@jhmi.edu

Principal Investigator

Ahmet Baschat, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

Johns Hopkins Hospital
Baltimore, Maryland, 21287
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Ahmet Baschat, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-23
Study Completion Date2031-12-01

Study Record Updates

Study Start Date2025-06-23
Study Completion Date2031-12-01

Terms related to this study

Keywords Provided by Researchers

  • Fetoscopic Endoluminal Tracheal Occlusion

Additional Relevant MeSH Terms

  • Congenital Diaphragmatic Hernia
  • Congenital Abnormalities
  • Neonatal Diseases and Abnormalities
  • Hernia, DIaphragmatic, Congenital
  • Internal Hernia
  • Hernia
  • Pathological Conditions, Anatomical
  • Pathological Conditions, Signs and Symptoms